Kazuto Nishio

Research interests

Publications

• Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.00771

• Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.00771

• B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

  Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-17-2852

• B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity

  Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-17-2852

• Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

  Annals of Oncology · 2017 · 10.1093/annonc/mdx183

• DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance

  International Journal of Cancer · 2017 · 10.1002/ijc.30870

• EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

  Clinical Cancer Research · 2015 · 10.1158/1078-0432.ccr-15-1046

• LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.45.0981

• The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

  Oncogene · 2013 · 10.1038/onc.2013.547

• The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer

  Oncogene · 2013 · 10.1038/onc.2013.547

• Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

  Clinical Cancer Research · 2012 · 10.1158/1078-0432.ccr-12-0392

• FGFR2 gene amplification and clinicopathological features in gastric cancer

  British Journal of Cancer · 2012 · 10.1038/bjc.2011.603

• FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

  Hepatology · 2012 · 10.1002/hep.25956

• FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma

  Hepatology · 2012 · 10.1002/hep.25956

• Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

  Clinical Cancer Research · 2012 · 10.1158/1078-0432.ccr-12-0392

• Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-10-2798

• Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

  Science Translational Medicine · 2011 · 10.1126/scitranslmed.3002442

• Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

  Journal of Thoracic Oncology · 2011 · 10.1097/jto.0b013e3182307f98

• Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

  British Journal of Cancer · 2011 · 10.1038/bjc.2011.129

• Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer

  British Journal of Cancer · 2011 · 10.1038/bjc.2011.129

• Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-10-2638

• Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-10-2638

• Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-10-2798

• FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth

  Cancer Research · 2010 · 10.1158/0008-5472.can-09-2161

• FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

  Annals of Oncology · 2010 · 10.1093/annonc/mdq585

• EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line

  Molecular Cancer Therapeutics · 2008 · 10.1158/1535-7163.mct-07-2263

• EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line

  Molecular Cancer Therapeutics · 2008 · 10.1158/1535-7163.mct-07-2263

• Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)

  British Journal of Cancer · 2007 · 10.1038/sj.bjc.6603949

• Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor

  Cancer Science · 2007 · 10.1111/j.1349-7006.2007.00510.x

• Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients

  Breast Cancer Research and Treatment · 2006 · 10.1007/s10549-006-9175-2

• Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells

  Oncogene · 2006 · https://doi.org/10.1038/sj.onc.1210084

• Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer

  Clinical Cancer Research · 2006 · 10.1158/1078-0432.ccr-05-2324

• Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients

  Breast Cancer Research and Treatment · 2006 · 10.1007/s10549-006-9175-2

• Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib

  International Journal of Cancer · 2005 · 10.1002/ijc.20985

• Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib

  International Journal of Cancer · 2005 · 10.1002/ijc.20985

• Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.

  PubMed · 2003

Current projects

No projects listed.